Cell and gene therapy products help address cellular dysfunction and damage by replacing missing or malfunctioning genes. With the use of cell-based and gene-based medicines, healthcare providers can potentially treat chronic and life-threatening conditions like cancer, diabetes, cardiovascular diseases, and neurological disorders.
Market key trends:
Advancements in gene therapy technologies is one of the key trends driving the growth of cell and gene therapy market. Continuous research and development activities are being carried out to enhance gene delivery methods and improve therapeutic efficacy and safety of various gene therapy products. CRISPR/Cas9 gene editing technology has emerged as a promising tool for correcting genetic mutations and designing novel gene therapies. Several startups focusing on developing CRISPR-based therapies have attracted significant funding over the past few years. Moreover, establishment of large-scale gene and cell therapy manufacturing facilities by major players to boost commercial production will further support the market growth during the forecast period.
Segment Analysis
The global cell and gene therapy market is segmented based on therapy, therapy type, end users and geography. By therapy type, cell therapy dominates the market and accounts for the largest share. Cell therapy has shown promising results for treating various chronic diseases. Within cell therapy, CD19 CAR-T cell therapy segment holds the highest share as it is an approved therapy for treating certain blood cancers. By therapy, cancer accounts for the highest share as most of the cell and gene therapy products are approved for treating cancer.
Key Takeaways
Global Cell And Gene Therapy Market Size is expected to witness high growth over the forecast period driven by rising incidence of cancer and other chronic diseases, advances in science and technology.
Regional analysis: North America currently dominates the market due to extensive research activities, increasing funding for cell and gene therapy research. presence of key market players, and availability of reimbursements. Europe holds the second position due to supportive government initiatives for research and development. Asia Pacific is expected to grow at the fastest pace due to expansion of healthcare infrastructure, rising healthcare expenditure and growing collaborations between regional and global market players.
Key players operating in the cell and gene therapy market are Novartis AG, Gilead Sciences, Inc., Bluebird Bio, Inc., Spark Therapeutics, Inc., Celgene Corporation, Human Stem Cells Institute, Anthropic, Inc. Novartis leads the market due to its commercially approved CAR-T therapies, Kymriah and Tecartus. Gilead has a strong pipeline of CAR-T therapies in development which is expected to drive its growth over the forecast period.
Explore More Related Article On This Topic: https://www.pressreleasebulletin.com/cell-and-gene-therapy-market-demand/
Explore More Related Article: http://insightprobe.weebly.com/blog/global-land-mobile-radio-lmr-systems-market-is-estimated-to-witness-high-growth-owing-to-opportunity-for-public-safety-applications
Comments
0 comment